Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
NCT05096338 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-03-23
Summary
This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of health (such as race, gender identity, education, occupation, access to health services and economic resources). Patients on this study will have echocardiograms, blood draws, and answer questions about their symptoms and activity level. Patients will be followed on this study for up to 5 years.
Conditions
- Prostate Cancer
- Cardiotoxicity
- Drug-Related Side Effects and Adverse Reactions
- Cardiovascular Diseases
Interventions
- OTHER
-
Social Determinants of Health
We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
Sponsors & Collaborators
- collaborator OTHER
-
Abramson Cancer Center at Penn Medicine
lead OTHER
Principal Investigators
-
Bonnie Ky, MD, MSCE · University of Pennsylvania
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-27
- Primary Completion
- 2029-11-30
- Completion
- 2029-11-30
Countries
- United States
Study Locations
More Related Trials
-
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
NCT06163924 ·Status: RECRUITING
-
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
NCT07223385 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)
NCT03193138 ·Status: COMPLETED
-
Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
NCT00536653 ·Status: COMPLETED ·Phase: NA
-
Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer
NCT00455624 ·Status: COMPLETED
-
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
NCT00703768 ·Status: UNKNOWN
-
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
NCT01006395 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not
NCT00688532 ·Status: COMPLETED
-
RElugolix VErsus LeUprolide Cardiac Trial
NCT05320406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer
NCT01226888 ·Status: TERMINATED
-
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
NCT02903368 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
NCT01383863 ·Status: COMPLETED
-
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT05100472 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
NCT01023061 ·Status: COMPLETED ·Phase: PHASE2
-
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
NCT05611307 ·Status: TERMINATED
-
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma
NCT04567875 ·Status: UNKNOWN
-
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
NCT02229253 ·Status: COMPLETED
-
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT00005044 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database
NCT06902441 ·Status: COMPLETED
-
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
NCT00003653 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
NCT04530552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
NCT04523207 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
NCT04775355 ·Status: RECRUITING